Futura Medical plc Stock price

Equities

FUM

GB0033278473

Biotechnology & Medical Research

Delayed London S.E. 12:35:16 2024-03-28 pm EDT 5-day change 1st Jan Change
40.5 GBX +4.38% Intraday chart for Futura Medical plc +3.85% +58.82%
Sales 2023 * 3.1M 3.91M Sales 2024 * 10.08M 12.71M Capitalization 122M 154M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 36.9 x
Net cash position 2023 * 7.73M 9.74M Net cash position 2024 * 2.69M 3.4M EV / Sales 2024 * 11.8 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 12
Yield 2023 *
-
Yield 2024 *
-
Free-Float 67.12%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Futura Medical plc

1 day+4.38%
1 week+3.85%
1 month-5.48%
3 months+56.98%
6 months-2.41%
Current year+58.82%
More quotes
1 week
37.00
Extreme 37
40.50
1 month
37.00
Extreme 37
43.00
Current year
25.50
Extreme 25.5
47.80
1 year
23.28
Extreme 23.2816
67.00
3 years
23.28
Extreme 23.2816
67.00
5 years
7.16
Extreme 7.1601
84.00
10 years
5.65
Extreme 5.65
95.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 01-05-31
Director of Finance/CFO - 18-02-19
Chief Tech/Sci/R&D Officer - 16-03-30
Members of the board TitleAgeSince
Chairman 68 21-10-07
Director/Board Member 67 Jan. 08
Chief Executive Officer - 01-05-31
More insiders
Date Price Change Volume
24-03-28 40.5 +4.38% 359,491
24-03-27 38.8 +2.11% 300,237
24-03-26 38 -0.65% 205,390
24-03-25 38.25 +1.19% 198,428
24-03-22 37.8 -3.08% 317,967

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.405 GBP
Average target price
1.26 GBP
Spread / Average Target
+211.11%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Futura Medical plc - London S.E.